Longeveron Inc
Change company Symbol lookup
Select an option...
LGVN Longeveron Inc
DPDW Deep Down Inc
WOLF Wolfspeed Inc
PAVM PAVmed Inc
CNBP Cornerstone Bancorp Inc
UPS United Parcel Service Inc
RHHBY Roche Holding AG
EGP Eastgroup Properties Inc
PMT PennyMac Mortgage Investment Trust
GS Goldman Sachs Group Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Longeveron Inc. is a clinical stage biotechnology company, which is developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. It is sponsoring phase I and II clinical trials in various indications, such as aging frailty, Alzheimer's disease (AD), metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). It is evaluating Lomecel-B as a therapy for aging frailty and is being designed to reduce inflammation associated with aging frailty and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can promote physiological restoration to a more normal state. The Company has completed two multicenter trials in the United States for aging frailty.

Closing Price
$7.65
Day's Change
-0.20 (-2.55%)
Bid
--
Ask
--
B/A Size
--
Day's High
8.20
Day's Low
7.43
Volume
(Below Average)
Volume:
207,473

10-day average volume:
250,800
207,473

Display:

Providers:

UpdateCancel
6 providers
May 13, 2022
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results

EQNX::TICKER_START (NASDAQ:LGVN), EQNX::TICKER_END Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today...(Globe Newswire)

May 09, 2022
Longeveron Announces CEO Transition

EQNX::TICKER_START (NASDAQ:LGVN), EQNX::TICKER_END -Geoff Green stepping down as CEO, effective June 1, 2022 -K. Chris Min, M.D., Ph.D., current Chief Medical Officer, appointed Interim CEO -Nationwide search is underway for permanent CEO (Globe Newswire)

Longeveron to Announce First Quarter 2022 Financial Results on May 13, 2022

EQNX::TICKER_START (NASDAQ:LGVN), EQNX::TICKER_END Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today...(Globe Newswire)

April 14, 2022
Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer's Symposium; International Frailty and Sarcopenia Research Conference

Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today its Chief Science Officer, Co-Founder, and...(Globe Newswire)

April 13, 2022
Lifshitz Law Firm, P.C. Announces Investigations of Cassava Sciences, Inc. (NASDAQCM: SAVA), Coinbase Global, Inc. (NASDAQGS: COIN), HyreCar, Inc. (NASDAQCM: HYRE), and Longeveron Inc. (NASDAQCM: LGVN)

Cassava Sciences, Inc. (NASDAQCM: SAVA) Lifshitz Law PLLC announces that a class action complaint was filed against Cassava alleging Defendants made false and misleading statements and failed to disclose that: (i) the quality and integrity of the...(Globe Newswire)

Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027

FinancialNewsMedia.com News Commentary - Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent that it interferes with a person's daily life and activities. These functions...(PR Newswire)

Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer's Trial

Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today a Cooperative Research and Development...(Globe Newswire)

April 05, 2022
Longeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer

Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and other specific life-threatening conditions, announced today the addition of K. Chris...(Globe Newswire)

March 31, 2022
R&D Efforts for Alzheimer's Therapies on the Rise with over 120 Drugs in Development

FinancialNewsMedia.com News Commentary - Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia among the elderly, accounting for between 60% and 80% of cases in the US, Japan and...(PR Newswire)

Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer's Disease in Alzheimer's & Dementia(R): The Journal of the Alzheimer's Association

Results Support Further Exploration of Therapeutic Potential of Lomecel-B to Slow Cognitive Decline, Improve Quality of Life for Alzheimer's Patients Phase 2 Trial Recently Launched With First Patient Treated (Globe Newswire)

March 24, 2022
Longeveron Presents at Second Euro-Geroscience Conference

Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management presented at the Second...(Globe Newswire)

March 15, 2022
Longeveron to Present at Oppenheimer 32nd Annual Healthcare Conference

Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive Officer...(Globe Newswire)

March 11, 2022
Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

Currently Enrolling Clinical Trials with Lomecel-B in Three Disease Indications: Hypoplastic Left Heart Syndrome (Phase 2a), Alzheimer's Disease (Phase 2a), and Covid-related Acute Respiratory Distress Syndrome (Phase 1) (Globe Newswire)

March 07, 2022
Longeveron to Announce Fourth Quarter and Full Year 2021 Financial Results, on March 11, 2022

Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its fourth...(Globe Newswire)

March 02, 2022
Longeveron to Present at Q1 Virtual Investor Summit Conference

Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive Officer...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.